… score, history of previous stroke or transient … Cost effectiveness analysis We evaluated the
most cost effective first-line (initially used) anticoagulant for the prevention of ischaemic stroke …

… treatment of venous thromboembolic disease: results of cost-effectiveness analyses 264
Secondary prevention of venous thromboembolism: results of clinical effectiveness analyses …

… in clinical practice, as the treatment quality in a trial setting … of cost-effectiveness analysis
included. In addition, the literature summarized in this review shows that NOACs versus warfarin …

… in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral
anticoagulants and warfarin. Clin Drug Investig 2015;35:109–19.doi:10.1007/s40261-014-0253-7 …

… in the economic burden of NVAF was predicted, and many cost-effectiveness analyses were
… in implementing strategies for the prevention of stroke in NVAF. The present systematic …

… than warfarin in Taiwan, and this is likely to be the main restriction of their use. In addition,
the results of cost-effectiveness analyses … disease progression, treatment patterns, healthcare …

… Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K …
for stroke prevention in patients with NVAF [48–51], and existing cost-effectiveness analyses in …

… compare cost-effectiveness of all DOACs and warfarin in a single … anticoagulant in the
prevention of ischemic stroke for patients with non-valvular AF and not contraindicated to warfarin …

… The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a HAS-…

… stroke in … reviewed Randomized Clinical Trial studies consistent with the present study
and identified 23 studies corroborating the higher cost-effectiveness of NOAC than warfarin …